Literature DB >> 26648610

Retapamulin.

.   

Abstract

Year:  2014        PMID： 26648610      PMCID： PMC4654036          DOI： 10.18773/austprescr.2015.013

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  5 in total

1.  Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin.

Authors:  Almena Free; Eli Roth; Marybeth Dalessandro; Joseph Hiram; Nicole Scangarella; Ribhi Shawar; Scott White
Journal:  Skinmed       Date:  2006 Sep-Oct

2.  Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.

Authors:  Lawrence Charles Parish; Joseph Lucius Jorizzo; John Jeffrey Breton; Joseph William Hirman; Nicole Elizabeth Scangarella; Ribhi Mohammad Shawar; Scott Matthew White
Journal:  J Am Acad Dermatol       Date:  2006-10-06       Impact factor: 11.527

3.  The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study.

Authors:  John F Tomayko; Gang Li; John J Breton; Nicole Scangarella-Oman; Marybeth Dalessandro; Michael Martin
Journal:  Adv Skin Wound Care       Date:  2013-03       Impact factor: 2.347

4.  Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial.

Authors:  S Koning; J C van der Wouden; O Chosidow; M Twynholm; K P Singh; N Scangarella; A P Oranje
Journal:  Br J Dermatol       Date:  2008-03-13       Impact factor: 9.302

5.  Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study.

Authors:  Arnold P Oranje; Olivier Chosidow; Sarvajnamurthy Sacchidanand; Gail Todd; Krishan Singh; Nicole Scangarella; Ribhi Shawar; Monique Twynholm
Journal:  Dermatology       Date:  2007       Impact factor: 5.366
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.